683 related articles for article (PubMed ID: 15070762)
21. Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine--induced immunity.
He Y; Manischewitz J; Meseda CA; Merchlinsky M; Vassell RA; Sirota L; Berkower I; Golding H; Weiss CD
J Infect Dis; 2007 Oct; 196(7):1026-32. PubMed ID: 17763325
[TBL] [Abstract][Full Text] [Related]
22. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
Gómez CE; Abaitua F; Rodríguez D; Esteban M
Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
[TBL] [Abstract][Full Text] [Related]
23. Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques.
Edghill-Smith Y; Venzon D; Karpova T; McNally J; Nacsa J; Tsai WP; Tryniszewska E; Moniuszko M; Manischewitz J; King LR; Snodgrass SJ; Parrish J; Markham P; Sowers M; Martin D; Lewis MG; Berzofsky JA; Belyakov IM; Moss B; Tartaglia J; Bray M; Hirsch V; Golding H; Franchini G
J Infect Dis; 2003 Oct; 188(8):1181-91. PubMed ID: 14551889
[TBL] [Abstract][Full Text] [Related]
24. Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge.
Pulford DJ; Gates A; Bridge SH; Robinson JH; Ulaeto D
Vaccine; 2004 Sep; 22(25-26):3358-66. PubMed ID: 15308360
[TBL] [Abstract][Full Text] [Related]
25. Live vaccinia-rabies virus recombinants, but not an inactivated rabies virus cell culture vaccine, protect B-lymphocyte-deficient A/WySnJ mice against rabies: considerations of recombinant defective poxviruses for rabies immunization of immunocompromised individuals.
Lodmell DL; Esposito JJ; Ewalt LC
Vaccine; 2004 Sep; 22(25-26):3329-33. PubMed ID: 15308356
[TBL] [Abstract][Full Text] [Related]
26. [Development of a numerically additive combined vaccine against tetanus and smallpox].
Mayr A; Baljer G; Wagner C; Sailer J
Zentralbl Bakteriol Mikrobiol Hyg A; 1985 Apr; 259(2):206-18. PubMed ID: 2990123
[TBL] [Abstract][Full Text] [Related]
27. Protective immunity against secondary poxvirus infection is dependent on antibody but not on CD4 or CD8 T-cell function.
Panchanathan V; Chaudhri G; Karupiah G
J Virol; 2006 Jul; 80(13):6333-8. PubMed ID: 16775321
[TBL] [Abstract][Full Text] [Related]
28. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine.
Vollmar J; Arndtz N; Eckl KM; Thomsen T; Petzold B; Mateo L; Schlereth B; Handley A; King L; Hülsemann V; Tzatzaris M; Merkl K; Wulff N; Chaplin P
Vaccine; 2006 Mar; 24(12):2065-70. PubMed ID: 16337719
[TBL] [Abstract][Full Text] [Related]
29. Paramunity-inducing effects of vaccinia strain MVA.
Vilsmeier B
Berl Munch Tierarztl Wochenschr; 1999 Sep; 112(9):329-33. PubMed ID: 10507181
[TBL] [Abstract][Full Text] [Related]
30. Studies on in vitro expression and in vivo immunogenicity of a recombinant MVA HIV vaccine.
Liu J; Wyatt LS; Amara RR; Moss B; Robinson HL
Vaccine; 2006 Apr; 24(16):3332-9. PubMed ID: 16472543
[TBL] [Abstract][Full Text] [Related]
31. Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection.
Wang Z; La Rosa C; Lacey SF; Maas R; Mekhoubad S; Britt WJ; Diamond DJ
J Clin Virol; 2006 Mar; 35(3):324-31. PubMed ID: 16388983
[TBL] [Abstract][Full Text] [Related]
32. A single vaccination with non-replicating MVA at birth induces both immediate and long-term protective immune responses.
Cheminay C; Körner J; Bernig C; Brückel M; Feigl M; Schletz M; Suter M; Chaplin P; Volkmann A
Vaccine; 2018 Apr; 36(18):2427-2434. PubMed ID: 29599088
[TBL] [Abstract][Full Text] [Related]
33. Vaccination with a Modified Vaccinia Virus Ankara-based vaccine protects mice from allergic sensitization.
Albrecht M; Suezer Y; Staib C; Sutter G; Vieths S; Reese G
J Gene Med; 2008 Dec; 10(12):1324-33. PubMed ID: 18816482
[TBL] [Abstract][Full Text] [Related]
34. Development of smallpox vaccine candidates with integrated interleukin-15 that demonstrate superior immunogenicity, efficacy, and safety in mice.
Perera LP; Waldmann TA; Mosca JD; Baldwin N; Berzofsky JA; Oh S
J Virol; 2007 Aug; 81(16):8774-83. PubMed ID: 17553867
[TBL] [Abstract][Full Text] [Related]
35. Clonal vaccinia virus grown in cell culture as a new smallpox vaccine.
Weltzin R; Liu J; Pugachev KV; Myers GA; Coughlin B; Blum PS; Nichols R; Johnson C; Cruz J; Kennedy JS; Ennis FA; Monath TP
Nat Med; 2003 Sep; 9(9):1125-30. PubMed ID: 12925845
[TBL] [Abstract][Full Text] [Related]
36. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.
Hodge JW; Poole DJ; Aarts WM; Gómez Yafal A; Gritz L; Schlom J
Cancer Res; 2003 Nov; 63(22):7942-9. PubMed ID: 14633725
[TBL] [Abstract][Full Text] [Related]
37. Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus.
Earl PL; Americo JL; Wyatt LS; Espenshade O; Bassler J; Gong K; Lin S; Peters E; Rhodes L; Spano YE; Silvera PM; Moss B
Proc Natl Acad Sci U S A; 2008 Aug; 105(31):10889-94. PubMed ID: 18678911
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults.
Frey SE; Newman FK; Kennedy JS; Ennis F; Abate G; Hoft DF; Monath TP
Vaccine; 2009 Mar; 27(10):1637-44. PubMed ID: 19071184
[TBL] [Abstract][Full Text] [Related]
39. Different contribution of co-stimulatory molecules B7.1 and B7.2 to the immune response to recombinant modified vaccinia virus ankara vaccine expressing prM/E proteins of Japanese encephalitis virus and two hepatitis B virus vaccines.
NAM JH; BANG HS; CHO HW; CHUNG YH
Acta Virol; 2007; 51(2):125-30. PubMed ID: 17900219
[TBL] [Abstract][Full Text] [Related]
40. An accelerated vaccine schedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses.
Fournillier A; Gerossier E; Evlashev A; Schmitt D; Simon B; Chatel L; Martin P; Silvestre N; Balloul JM; Barry R; Inchauspé G
Vaccine; 2007 Oct; 25(42):7339-53. PubMed ID: 17875349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]